COVID-19 and Cardiovascular System: Pathophysiology, Pathomorphology, Complications, Long-Term Prognosis

COVID-19 and Cardiovascular System: Pathophysiology, Pathomorphology, Complications, Long-Term Prognosis

Like other respiratory viruses, COVID-19 has extrapulmonary manifestations. The effect of the virus leads to the cardiovascular system (CVS) damage in particular, which pathophysiological mechanisms are not fully understood. In this article we analyze modern ideas about COVID-19, consider possibleli...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. S. Petrikov, A. A. Ivannikov, M. K. Vasilchenko, A. N. Esaulenko, Kh. G. Alidzhanova
Format:	Article
Language:	Russian
Published:	Sklifosovsky Research Institute for Emergency Medicine, Public Healthcare Institution of Moscow Healthcare Department 2021-04-01
Series:	Неотложная медицинская помощь
Subjects:	covid-19 sars-cov-2 cardiovascular system cardiovascular diseases angiotensin converting enzyme 2 (ace2) pathophysiology pathomorphology comorbidity complications long-term prognosis
Online Access:	https://www.jnmp.ru/jour/article/view/1069
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

Angiotensin converting enzyme 2 in patients with sepsis associate with comorbidities but neither with mortality nor with organ failure
by: Felix Forsberg, et al.
Published: (2025-04-01)

Actual issues of the pathogenesis of COVID-19 and possible measures for the prevention of severe forms of the disease
by: Kh. G. Omarova, et al.
Published: (2021-06-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

Coronavirus disease 2019 and cardiovascular disease
by: Jenn-Yeu Song, et al.
Published: (2023-01-01)

Correlation between orthostatic intolerance in children and levels of ACE2-Ang(1-7)-Mas axis and vitamin D
by: Yao Xiao, et al.
Published: (2025-05-01)

Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity
by: Evelyn F Okal, et al.
Published: (2025-02-01)

Comparative Study of Pathomorphological Changes in Animal Lung Tissue when Modeling Infection Caused by the SARS-CoV-2 Virus
by: A. V. Shipovalov, et al.
Published: (2024-07-01)

Pathophysiological mechanisms of coronavirus disease (COVID-19) progression and fatal complications in patients with diabetes
by: T. O. Briukhanova, et al.
Published: (2020-10-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-01-01)

Etiological and immunopathogenetic aspects of multiorgan failure development in coronavirus disease (COVID-19)
by: T. V. Ashcheulova, et al.
Published: (2024-07-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Angiotensin I converting enzyme (ACE) inhibitory activity and antihypertensive effects of rice peptides
by: Jingjing Dong, et al.
Published: (2022-11-01)

Optimization of Protein Hydrolysate from Earthworms (<i>Perionyx excavatus</i>) of Angiotensin-I-Converting Enzyme Inhibitory Activity by One Variable at a Time
by: Phong Thanh Bui, et al.
Published: (2025-01-01)

Effects of SARS-CoV-2 on the cardiovascular system: More issues to be addressed
by: Yang Liu
Published: (2020-07-01)

Polymorphisms in the ACE I/D (<i>rs</i>4646994) and ACE2 G8790A (<i>rs</i>2285666) in Young Children Living in the Amazon Region and SARS-CoV-2 Infection
by: Yan Cardoso Pimenta, et al.
Published: (2024-11-01)

Daphnetin may protect from SARS-CoV-2 infection by reducing ACE2
by: Qian-wen Yang, et al.
Published: (2024-12-01)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study
by: Weihong Zeng, et al.
Published: (2025-05-01)

How COVID-19 Can Damage the Heart? – Association of Cardiac Injury with COVID-19: A Narrative Review
by: Catarina Gregório, et al.
Published: (2025-05-01)

COVID 19 infection: Pediatric perspectives
by: Adebayo Adeyinka, et al.
Published: (2021-02-01)

Angiotensin Converting Enzyme Inhibitors: Interaction Issues in Patients with Glaucoma and Arterial Hypertension. Review
by: S. I. Makogon, et al.
Published: (2023-12-01)

Characterization and angiotensin-converting enzyme inhibitory activity of peptides of seabuckthorn (Hippophae rhamnoides L.) seed meal
by: Yuanju Zheng, et al.
Published: (2024-07-01)

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
by: Naci Şenkal, et al.
Published: (2020-07-01)

Ace gene insertion/deletion polymorphism is associated with glioblastoma in an Iranian population: a case-control study
by: A. Moqadami, et al.
Published: (2023-05-01)

Myocardial and Renal Renin–Angiotensin System Enzyme Activity in Dogs
by: Emma C. Weitzhandler, et al.
Published: (2025-07-01)

Choosing the Right Angiotensin Converting Enzyme Inhibitors; Gender –Specific Approach
by: Neena Elsa Varghese, et al.
Published: (2024-12-01)

Evaluating Serum Troponin as a Mortality Predictor in COVID-19: Two Center Prospective Study
by: Muhannd M. Jawad, et al.
Published: (2025-07-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Development and characterization of a fully humanized ACE2 mouse model
by: Chunyu Ge, et al.
Published: (2025-07-01)

THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION
by: D. B. Nebieridze, et al.
Published: (2015-12-01)

SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
by: S. R. Gilyarevskiy, et al.
Published: (2016-01-01)

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

Using Nano-Luciferase Binary (NanoBiT) Technology to Assess the Interaction Between Viral Spike Protein and Angiotensin-Converting Enzyme II by Aptamers
by: Meng-Wei Lin, et al.
Published: (2025-03-01)

Genetic association of ACE2 rs2285666 (C>T) and rs2106809 (A>G) and susceptibility to SARS-CoV-2 infection among the Ghanaian population
by: Alexander Owusu Boakye, et al.
Published: (2025-05-01)

Pulse Pressure Index as a Discriminator of Predicting the Cardiovascular Events in Hypertensive Patients Treated with Drugs Acting on Angiotensinogen-Angiotensin Pathway
by: Marwan S. Al-Nime, et al.
Published: (2019-06-01)

COVID-19 and Cardiovascular System. Part II. Post-COVID Syndrome
by: A. A. Ivannikov, et al.
Published: (2021-08-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)